Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039851097> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3039851097 abstract "Introduction: New pieces of evidence suggest that combining basal insulin with glucagone-like peptide 1 receptor agonists (GLP-1RA) in patients with type 2 diabetes could promptly ameliorate glucose control and prevent both hypoglycemic events and unnecessary weight gain compared to more intensive insulin regimens. Aim: To review the efficacy/effectiveness and safety of fixed-ratio combinations of basal insulin and GLP- 1RA (FRCs). Methods: Authors searched PubMed/MEDLINE, ClinicalTrials.gov, Cochrane Library, and Google Scholar for freely available original articles, randomized clinical trials (RCTs), clinical reviews, and meta-analysis written in English until January 2020. Results: FRCs provide significative reductions in HbA1c levels in both insulin-naïve (-1.4% to -2%) and insulin- experienced (-1.5% to -2%) type 2 diabetic patients with moderate glucose impairment. More patients achieved the recommended glycemic targets on FRCs compared to those on mono-therapy with basal insulin or GLP-1RAs. The intensification with FRCs results in better glycemic control compared to basal insulin at fasting as well as during the postprandial state. The frequency of hypoglycemia is similar or lower in patients treated with FRCs than in those on basal insulin alone at a similar dose. Weight trend can be variable, ranging from -2.7 to +2 Kg for iDegLira and -0.7 to -1.3 Kg for iGlar- Lixi. However, a lower weight gain is obtained with iDegLira compared to iDeg (-2.2 to -2.5 Kg), iGlar (-1.7 to -3.2 Kg), and basal-bolus (-3.6 Kg) as well as with iGlarLixi compared to iGlar (-1.4 Kg). Discussion and Conclusion: FRCs should be considered to safely improve the metabolic control in type 2 diabetic patients with moderate glycemic impairment while on oral medications, basal oral regimen or GLP-1RAs. However, a few but significative pieces of evidence suggest that FRCs could be a safe and effective treatment instead of a low dose basal-bolus intensification for patients with mild or moderate glucose impairment in order to reduce the risk of hypoglycemia and unnecessary weight gain, and for simplifying treatment regimen as well." @default.
- W3039851097 created "2020-07-10" @default.
- W3039851097 creator A5024082952 @default.
- W3039851097 creator A5027919692 @default.
- W3039851097 creator A5032891061 @default.
- W3039851097 creator A5074195972 @default.
- W3039851097 date "2021-05-04" @default.
- W3039851097 modified "2023-09-27" @default.
- W3039851097 title "Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature" @default.
- W3039851097 doi "https://doi.org/10.2174/1871530320666200705211224" @default.
- W3039851097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32628602" @default.
- W3039851097 hasPublicationYear "2021" @default.
- W3039851097 type Work @default.
- W3039851097 sameAs 3039851097 @default.
- W3039851097 citedByCount "4" @default.
- W3039851097 countsByYear W30398510972021 @default.
- W3039851097 countsByYear W30398510972022 @default.
- W3039851097 countsByYear W30398510972023 @default.
- W3039851097 crossrefType "journal-article" @default.
- W3039851097 hasAuthorship W3039851097A5024082952 @default.
- W3039851097 hasAuthorship W3039851097A5027919692 @default.
- W3039851097 hasAuthorship W3039851097A5032891061 @default.
- W3039851097 hasAuthorship W3039851097A5074195972 @default.
- W3039851097 hasConcept C126322002 @default.
- W3039851097 hasConcept C134018914 @default.
- W3039851097 hasConcept C168563851 @default.
- W3039851097 hasConcept C2776478404 @default.
- W3039851097 hasConcept C2777180221 @default.
- W3039851097 hasConcept C2778024521 @default.
- W3039851097 hasConcept C2778199505 @default.
- W3039851097 hasConcept C2779306644 @default.
- W3039851097 hasConcept C2780473172 @default.
- W3039851097 hasConcept C2780668416 @default.
- W3039851097 hasConcept C2910068830 @default.
- W3039851097 hasConcept C555293320 @default.
- W3039851097 hasConcept C71924100 @default.
- W3039851097 hasConcept C90924648 @default.
- W3039851097 hasConceptScore W3039851097C126322002 @default.
- W3039851097 hasConceptScore W3039851097C134018914 @default.
- W3039851097 hasConceptScore W3039851097C168563851 @default.
- W3039851097 hasConceptScore W3039851097C2776478404 @default.
- W3039851097 hasConceptScore W3039851097C2777180221 @default.
- W3039851097 hasConceptScore W3039851097C2778024521 @default.
- W3039851097 hasConceptScore W3039851097C2778199505 @default.
- W3039851097 hasConceptScore W3039851097C2779306644 @default.
- W3039851097 hasConceptScore W3039851097C2780473172 @default.
- W3039851097 hasConceptScore W3039851097C2780668416 @default.
- W3039851097 hasConceptScore W3039851097C2910068830 @default.
- W3039851097 hasConceptScore W3039851097C555293320 @default.
- W3039851097 hasConceptScore W3039851097C71924100 @default.
- W3039851097 hasConceptScore W3039851097C90924648 @default.
- W3039851097 hasLocation W30398510971 @default.
- W3039851097 hasLocation W30398510972 @default.
- W3039851097 hasOpenAccess W3039851097 @default.
- W3039851097 hasPrimaryLocation W30398510971 @default.
- W3039851097 hasRelatedWork W1036392 @default.
- W3039851097 hasRelatedWork W14748982 @default.
- W3039851097 hasRelatedWork W15954137 @default.
- W3039851097 hasRelatedWork W1739382 @default.
- W3039851097 hasRelatedWork W18718624 @default.
- W3039851097 hasRelatedWork W7710465 @default.
- W3039851097 hasRelatedWork W9343845 @default.
- W3039851097 hasRelatedWork W12611928 @default.
- W3039851097 hasRelatedWork W18644294 @default.
- W3039851097 hasRelatedWork W4206524 @default.
- W3039851097 isParatext "false" @default.
- W3039851097 isRetracted "false" @default.
- W3039851097 magId "3039851097" @default.
- W3039851097 workType "article" @default.